In the work of Villa et al., 50 HCC patients were differentiated by wild-type ERα and ER α mRNA variant lacking exon 5 (ERΔ5) phenotypes and the therapeutic efficacy of TMX was confirmed in patients with wild-type phenotype (Villa et al., 1996). This evidence concerns the gene ESR1 and hepatocellular carcinoma.